Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Jonathan P. Graham, Executive Vice President and General Counsel at Amgen Inc . (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $158 billion and "GOOD" financial ...

This week, hearings scheduled before the Supreme Court of Canada, Federal Court of Appeal, and Federal Court included matters ...

Piper Sandler, a well-known investment firm, increased its price target on shares of Amgen (NASDAQ:AMGN) to $329.00, up from the previous target of $310.00. The firm has maintained its Overweight ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...

Cadrenal Therapeutics, a biopharmaceutical company listed on the Nasdaq under the ticker symbol CVKD, made a public announcement of leadership changes through an 8-K SEC filing on February 4, 2025.

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...